Business
POLB 001 patent portfolio strengthened
POLB 001 patent portfolio strengthened.
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n \n \n \n Poolbeg Pharma plc\n \n \n \n \n \n \n \n POLB 001 patent portfolio strengthened through granting of US patent\n \n \n \n \n \n \n \n Key highlights\n \n \n \n ·\n \n Patent granted for use of certain p38 MAP kinase inhibitors for the treatment of hypercytokinaemia\n \n \n \n ·\n \n Allows for use in combination with an antiviral agent\n \n \n \n ·\n \n Patent enhances the robust IP portfolio protecting Poolbeg's growing pipeline\n \n \n \n \n \n \n 8 March 2023\n -\n \n Poolbeg Pharma\n \n (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'),\n a leading infectious disease focused biopharmaceutical company, announces that further to its announcement on\n \n 4 October 2022\n \n , it\n has been granted a patent by the US Patent and Trademark Office (USPTO) for methods of treating hypercytokinaemia using POLB 001,\n a small molecule immunomodulator\n being developed to address the unmet medical need arising from severe influenza and other acute inflammatory conditions.\n \n \n \n \n \n \n \n The USPTO granted a patent for the use of POLB 001 and related p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of hypercytokinaemia (or \"cytokine storm\"), including hypercytokinaemia that occurs due to viral infection such as an influenza virus, cancer or an autoimmune response, through the modulation of the immune response (reducing the body's hyperinflammatory response).\n \n \n \n \n \n Poolbeg has a worldwide license for POLB 001 for all uses in humans and is developing a strong IP portfolio with US patent protection in place covering the use of a wide range of p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of symptoms of severe influenza and hypercytokinaemia and a European patent for the class of p38 MAP kinase inhibitors for use in the treatment of severe influenza.\n \n \n \n \n \n In\n \n \n January 2022,\n \n \n the Company filed a\n patent application to seek class protection for the novel use of p38 inhibitors in CAR T cell treatment. This opens up a significant new market opportunity for POLB 001 beyond severe influenza. Poolbeg continues to explore opportunities to expand its IP around this asset to cover new disease areas which could enhance the value of the asset.\n \n \n \n \n \n The Company contin...